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Abstract
Background: General Practitioners (GPs) play a central role in controlling an important risk
factor for cardiovascular diseases, i.e. cholesterol levels in serum. In the past few decades different
studies have been published on the effect of treating hyperlipidemia with statins. Guidelines for
treatment have been adopted. We investigated the consequences on the practice of GPs screening
cholesterol levels and on the timing of starting statin prescription.
Methods: For this descriptive study, data from the Intego database were used, composed with
data from the electronic medical records (EMR) of 47 general practices in Flanders. GPs had not
received special instructions for testing specific patients. For each patient the mean cholesterol
level per year was calculated. A patient belonged to the group with lipid-lowering drugs if there
was at least one prescription of the drug in a year in his EMR. Mixed model linear regression models
were used to quantify the effect of covariates on total cholesterol values.
Results: In the period 1994–2003 total cholesterol was tested in 47,254 out of 139,148 different
patients. Twelve percent of those tested took lipid-lowering medication. The proportion of
patients with at least one cholesterol test a year, increased over a period of ten years in all age
groups, but primarily for those over the age of 65.
The mean cholesterol level decreased in the treated as well as in the non-treated group. Of the
patients with a cardiovascular antecedent who were on lipid-lowering drugs in 2003, 56% had a
cholesterol level ≤ 199 mg/dl, 31% between 200–239 and 13% over 240 mg/dl.
Conclusion: The indications for testing and treating cholesterol levels broadened considerably in
the period examined. In 2003 cholesterol was tested in many more patients and patients were
already treated at lower cholesterol values than in previous years. Comparisons of cholesterol
levels over different years should therefore be interpreted with caution as they are a reflection of
changes in medical care, and not necessarily of efficacy of treatment.
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Background
For the primary and secondary prevention of cardiovascu-
lar diseases, it is important that the General Practitioner
(GP) knows the cardiovascular risk factors of his/her
patients and, if necessary, reduces the risk through an
intervention. Primary care is the preferred setting for
improvement of the risk factors, because the GP is the
patient's first and most prominent contact with health
care [1,2].
Over the last few decades death rates from coronary heart
disease have decreased by 50% in the United States,
Europe and Australia [3]. Despite this, heart disease
remains the greatest cause of death in industrialized coun-
tries. It is possible to control a number of major risk fac-
tors: smoking, hypercholesterolaemia, hypertension,
glucose intolerance and obesity. Hypercholesterolemia is
one of the major risk factors for cardiovascular diseases [4]
and the positive effect of lowering cholesterol levels in the
serum has been proved in several studies [5-7]. The effect
of lowering cholesterol levels on primary prevention for
cardiovascular diseases was pointed out in a study of
patients with an increased cholesterol, namely 272 mg/dl
at the start of the study [6]. Recently it has been suggested
that the control of three risk factors in primary prevention,
i.e. smoking, total cholesterol and blood pressure, would
be responsible for half of the decrease in mortality for cor-
onary diseases in England and Wales [8,9].
What is interesting is that high cholesterol values can be
controlled relatively easily by the use of lipid-lowering
medication in most cases. Moreover, it would take only a
minor decrease in cholesterol levels in the whole popula-
tion to have a major effect on mortality, in contrast with
highly sophisticated interventions and treatments, which
merely have a positive effect on mortality in a restricted
number of people [10,11]. In Belgium 90% [12] and in
Denmark 82% [13] of the lipid-lowering medication is
started by the GP. The GP can play an important role in
recognizing the cardiovascular risk factors of his/her
patients. After all, they treat patients for a whole range of
diseases, long before an infarction or cerebrovascular acci-
dent (CVA) occurs.
Using data from a database of EMRs of GPs in Flanders,
we examined trends in testing cholesterol and prescribing
of lipid-lowering drugs in general practice in the period
1994–2003 and also investigated whether the target of
optimal treatment was reached in patients with and with-
out cardiovascular risk factors. This study is based on
information from a database containing data from the
EMR of GPs.
Methods
Design
This is a descriptive study, based on data from the Intego
database.
The Intego database [14,15]
The Intego database is composed of data from the EMRs
of GPs using the medical software program Medidoc®. In
the spring of 2004, data were collected from 47 general
practices with 55 GPs, spread over Flanders. All diagnoses
and medical prescriptions had been recorded by the GP
using thesauri with specific codes. Laboratory results were
sent from the laboratory to the general practice via a pro-
tected connection and were automatically imported with
program-specific keywords into the EMR. General prac-
tices were selected on the basis of high quality of registra-
tion. The database contains information on diagnoses,
drug prescriptions and laboratory results of 140,000 dif-
ferent patients. The population sample from the database
is representative of the Flemish population on age, sex
and geographical spread [16]. Epidemiological figures
have been calculated from 1994 on. The number of differ-
ent patients seen in a calendar year in a practice is the
yearly contact group (YCG) and this figure is used as a
denominator. Only for the patients in the YCG of 2003
was a calculation made as to how many of them had a
cholesterol test in the previous five years.
Measurements
The GPs were left to decide for themselves which patients
would have their cholesterol levels tested. For this study
GPs were not given specific directives for prescribing
blood tests in specific patients. In this way, tests were
obtained in patients at high risk but also in patients who
consulted for other reasons. The total cholesterol level was
examined by the local laboratory and not by one central
laboratory. Because this study had not the intention to
determine an exact cardiovascular risk profile, a complete
lipid profile was not considered in this study.
Analysis
The mean cholesterol value was calculated per patient,
based on all the tests performed during a specific year in
the period 1994–2003. For the conversion from mg/dl to
mmol/l values are multiplied by 0.0259 and for the
reverse by 38.61 [17]. Each patient was classified in the
group treated with lipid-lowering medication in a specific
year, if at least one prescription was recorded for this class
of medication in the year concerned. If a prescription had
been recorded in at least one year of the period 1994–
2003, the patient was added to the group of treated
patients.
Patients were included in the group with a cardiovascular
antecedent, if at least one of the following codes of theBMC Family Practice 2008, 9:39 http://www.biomedcentral.com/1471-2296/9/39
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International Classification of Primary Care (ICPC-2)
appeared in their medical history: K74 Ischaemic heart
disease with angina, K75 Acute myocardial infarction,
K76 Ischaemic heart disease without angina, K89 Tran-
sient cerebral ischaemia, K90 Stroke/Cerebrovascular acci-
dent, K91 Cerebrovascular disease, K92 Atherosclerosis/
peripheral vascular disease. The cut-off points for optimal
treatment of the total cholesterol levels were based on the
third report of the US National Cholesterol Education
Program [18]. A fasting total cholesterol <200 mg/dl is
good, between 200 and 239 is borderline high and ≥ 240
is too high.
Statistics
Because of the large number of observations, the follow-
ing formula was used for the standard error in the calcula-
tion of 95% confidence intervals around the difference in
cholesterol values,:  , where s1and  s2 are the
standard deviations and n1 and n2 the number of patients
in the two groups. The z test [19] was used to test statisti-
cal significance for the difference in cholesterol values.
Mixed model linear regression models incorporating an
unstructured covariance structure, accounting for repeated
measures within subjects and random effects at the prac-
tice level, were used to quantify the effect of the covariates
on the cholesterol values: fixed effects were defined as
treatment effect (defined as having ever been prescribed
lipid-lowering drugs), sex, age, time and the interaction
between time and treatment. These analyses were per-
formed using SAS software, version 9.1.
Results
Patients with a cholesterol test
In the period 1994–2003 the total cholesterol level was
tested at least once in 47,254 out of 139,148 patients
(54.56% women and 45.44% men). In those patients
131,000 cholesterol levels were calculated. Because of the
small number of tests administered to patients under age
24, only the patients over the age of 25 will be discussed,
i.e. 125,342 values and 43,197 different patients. Of all
the patients seen in the practice in 2003, 57% had their
cholesterol tested at least once in the preceding five years.
The proportion of patients with at least one cholesterol
test in the year 2003 in the age groups 25–44, 45–64, 65–
74 and 75+ amounts to 16%, 38%, 56% and 42% respec-
tively of the patients who had contacted the practice in
that year (Table 1). This is an increase compared with the
year 1994 of 4%, 8%, 16% and 14% respectively.
In the group with a cholesterol test, 5,768 patients
(12.21%) took a lipid-lowering drug, and the proportion
of patients taking medication in the age groups 25–44,
45–64, 65–74 and 75+, amounts to 6%, 26%, 41% and
35%, respectively, in the year 2003. In the period 1994–
2003 the proportion of patients taking lipid-lowering
drugs increased in the age group 65+ years and decreased
under this age (Table 1).
Patients on a lipid-lowering drug
The increase in the number of patients with a prescription
for a lipid-lowering drug resulted from the increasing use
of statins and not of fibrates. The proportion of patients of
the YCG, with at least one prescription for a statin in a spe-
cific year, increased from 0.47 in 1994 to 5.30% in 2003.
The increase was noticeable in all age groups particularly
after 1997. In the same period, there was only a slight
increase in the use of fibrates from 1.45 to 1.81%.
In 2003, GPs started their patients, specially the oldest age
group, on lipid-lowering drugs at lower cholesterol val-
ues, compared to 1994. In 1994 there was no great differ-
ence in cholesterol levels between the age groups
according to the cholesterol level at which lipid-lowering
drugs were started. In 2002 the levels were much lower in
the oldest age group than in the younger age groups (Fig-
ure 1).
In patients who had taken a cholesterol test, the propor-
tion with an additional cardiovascular risk factor (history
of cardiovascular disease, hypertension, diabetes)
s
n
s
n
1
2
1
2
2
2
+
Table 1: Proportion of patients with a cholesterol test and proportion with a cholesterol test and with lipid-lowering drugs, in the years 
1994 and 2003
age group proportion of patients in YCG* with cholesterol test proportion of patients with medication in the group with cholesterol test (%)
1994 2003 1994 2003
n%n%
25–44 2304 12.20 2924 15.80 8.72 5.54
45–64 3927 29.69 6493 37.91 32.82 26.17
65–74 2097 39.68 3705 55.91 33.14 40.89
75+ 925 27.78 2672 41.51 11.35 35.40
*yearly contact group (patients seen in the practice during a year)BMC Family Practice 2008, 9:39 http://www.biomedcentral.com/1471-2296/9/39
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increased from 29% to 34% between the years 1994–
1995 and 2002–2003. In this last group of patients with a
risk factor, the proportion of patients treated with a lipid-
lowering drug increased from 14% to 29%.
Cholesterol values
The results of the linear mixed model suggest that on aver-
age cholesterol levels were lower for patients that were not
on lipid-lowering drugs. With increasing age the total cho-
lesterol also increased. Females had a tendency to have
higher levels of total cholesterol in comparison to males,
p < 0.0001 (Table 2).
The mean total cholesterol level decreased significantly in
all patients between 1994 and 2003, especially in patients
taking lipid-lowering drugs. The range of decline in the
different age groups among patients taking lipid-lowering
medication was 10 mg/dl (from 41 to 51 mg/dl) (Table
3). The decrease appeared after 1999 in particular, three
years after the facilitation of the reimbursement of the
statins, which resulted in an increase in prescriptions of
these drugs (Figure 2). In the group without lipid-lower-
ing drugs we observed a similar decrease, but its magni-
tude reached only about a third compared to the group
with medication (Table 3, Figure 3).
The covariance estimates suggest that practices do not dif-
fer in their average cholesterol scores and that most varia-
tion occurs among patients within practices. (The variance
component within practices is more than 250 times larger
than the size of the variance component between prac-
tices).
Targets
Seventeen percent of the treated patients still had a total
serum cholesterol level which was considered to be ele-
vated, 47% were well regulated and 36% were borderline.
The proportion of patients treated with lipid-lowering
drugs in 2003, who had a previous history of a cardiovas-
cular disease and who reached the target of ≤ 199 mg/dl
was 56%. Only 43% of patients without such a disease
reached the target cholesterol level.
Mean total cholesterol levels in different age groups in the year before lipid-lowering drugs were started, in the period 1994– 2002; arrow indicates facilitation of the reimbursement of lipid-lowering drugs Figure 1
Mean total cholesterol levels in different age groups in the year before lipid-lowering drugs were started, in the period 1994–
2002; arrow indicates facilitation of the reimbursement of lipid-lowering drugs.
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Table 2: Fixed effects for the final model for total serum cholesterol
Effect Estimate Standard Error DF t Value Pr > |t|
Intercept 15079 294.18 49 51.26 <.0001
Treatment (no) -11179 344.77 88E3 -32.42 <.0001
Age 0.4457 0.008216 88E3 54.25 <.0001
Sex (female) 5.3299 0.2603 88E3 20.48 <.0001
Time -1.8572 0.09101 88E3 -20.41 <.0001
Treatment*Time -5.5843 0.1723 88E3 -32.40 <.0001BMC Family Practice 2008, 9:39 http://www.biomedcentral.com/1471-2296/9/39
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Discussion
Summary of main findings
In a relatively short period, the indication for testing and
drug treatment of elevated cholesterol levels as a cardio-
vascular risk factor has broadened greatly. Cholesterol
testing was performed in more patients and lipid-lower-
ing drugs were prescribed earlier. This was the case in all
age groups but especially in the over-45 years old group.
This has consequences for the mean values of total choles-
terol and, for this reason, comparisons of cholesterol lev-
els in the different years should be interpreted with
caution. The target of a cholesterol value below 199 mg/dl
was only reached in 47% of the patients treated in 2003.
Since the GP has access to the information on the choles-
terol level of approximately more than half of his/her
patients over the age of 25, he/she characterize the cardi-
ovascular risk profile of these patients by asking them
some additional questions. In this way the GP can play a
more important role in the primary and secondary pre-
vention of cardiovascular diseases.
The fact that GPs tested cholesterol levels at an earlier time
and prescribed lipid-lowering drugs sooner is probably
the result of the clinical studies that have shown the posi-
tive effects of lowering high cholesterol levels and of the
different guidelines that have been published in literature.
Advertising by the pharmacological industry and the facil-
itated reimbursement conditions of statins by the Belgian
health care system could have also played a role encourag-
ing the prescription of statins.
Table 3: Mean total cholesterol values (SD) and difference between the year 1994 and 2003 (95%CI) in patients with and without lipid-
lowering drugs
Age 1994 2003 difference
medication medication medication
without with without with without with
25–44 205 (38.07) 264 (41.51) 196 (38.50) 223 (48.78) 9 (6.83–11.17)* 41 (31.68–50.32)*
45–64 229 (40.58) 260 (40.68) 216 (36.28) 212 (40.82) 13 (11.14–14.86)* 48 (45.05–50.95)*
65–74 233 (40.78) 255 (41.78) 216 (35.40) 204 (37.35) 17 (14.40–19.60)* 51 (47.51–54.49)*
75+ 232 (45.95) 242 (42.73) 209 (39.79) 200 (38.34) 23 (19.34–26.66)* 42 (47.51–54.49)*
*p < 0.0001
Mean total cholesterol levels in patients with lipid-lowering drugs in different age groups, in the period 1994–2003; arrow indi- cates facilitation of the reimbursement of lipid-lowering drugs Figure 2
Mean total cholesterol levels in patients with lipid-lowering drugs in different age groups, in the period 1994–2003; arrow indi-
cates facilitation of the reimbursement of lipid-lowering drugs.
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Shortly after the introduction of statins in 1991 they were
only reimbursed by the Belgian Health Insurance after the
patient had followed a diet and if the GP had established
that the use of fibrates appeared to be ineffective. Only
from 1996 on was reimbursement facilitated and were
statins reimbursed if after three months of dieting the
total cholesterol remained over 250 mg/dl.
It is not clear why patients above age 65 years old were
tested more often and were also prescribed more fre-
quently lipid-lowering drugs than younger patients. This
was also found in another Belgian study [12]. One would
expect a more aggressive approach in younger age groups
as the benefits of lowering cholesterol would be larger
[20]. It might be possible that the elderly consult a doctor
more often for various reasons such as a larger number of
associated comorbidities; and, because of this, blood tests
were carried out more frequently.
The fact that serum cholesterol blood samples were exam-
ined by the local laboratory and not by one central labo-
ratory is not considered a problem. One can assume that
the quality of the laboratories is appropriate, because they
are regularly subjected to internal and external quality
controls, in order to reserve the right to have their activi-
ties reimbursed by the social security authorities.
Although the tests were done in many different laborato-
ries, retesting of patients was usually done in the same lab-
oratory as the one in which the first test was carried out.
Remarkably, scarcely half of the treated patients reached
the target of 199 mg/dl. Similar findings have been also
confirmed by other authors [1,13,21]. It appears that doc-
tors do not adapt their behaviour immediately to the cur-
rent guidelines. This is probably also due to the fact that it
is often difficult to motivate patients to take even more
medication to further decrease their cholesterol levels.
The findings of this study suggest that the practice of GPs
changed considerably in the period 1994–2003. Firstly,
they prescribed more cholesterol tests, also in patients
with less or no risk factors. Secondly, they already treated
patients with lower initial total serum cholesterol values.
Both these factors may have lead to a decrease in the aver-
age serum cholesterol levels that were measured. In addi-
tion, some of the change in cholesterol levels could be
explained by the effect of regression to the mean. Thus,
the overall positive evolution of the cholesterol levels
found in this study, may in part result from these factors,
and may not really reflect a lowering of the average serum
cholesterol in the population.
Strengths and the limitations of this study
The strength of this study is the fact that it originates from
primary care data. The GPs were not informed that choles-
terol levels would be examined and neither were they
given instructions as to which patients had to be tested.
Blood tests were performed for diverse reasons and with-
out any selection of patients. These results give an idea of
the "normal" working method of the GP. This method of
data collection makes it possible to examine such large
Mean total cholesterol levels in patients without lipid-lowering drugs, in different age groups in the period 1994–2003 Figure 3
Mean total cholesterol levels in patients without lipid-lowering drugs, in different age groups in the period 1994–2003.
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numbers of patients from different sex and age groups
[22].
A weak point in this study is the fact that the GPs in this
study are not a random sample of Flemish GPs. They were
not selected because they worked in a more, or less, scien-
tific way than their colleagues, but because of the high
quality of their registration [14]. The patient population,
however, is comparable with the population in Flanders
regarding age and sex.
It is possible that more tests were performed than
recorded, eg. by hospital consultants. This may have some
influence on the cholesterol levels before starting drug
treatment. In Belgium the GP is usually informed about
test results prescribed by consultants in such a way that he
is unable to include them in the laboratory module of
their EMR. Unfortunately, a lipid profile was not available
for analysis in this investigation.
Only in a small percentage of the GP files was the patients'
smoking status formally recorded. It was therefore not
possible to use our data to calculate the compliance with
current guidelines on cardiovascular risk control.
Comparison with literature
Our results agree with those of formerly published papers.
Filippi found that in Italy in one year, a cholesterol test
was carried out in 50% of patients in general practice
above the age of 65 [23]. In a study that examined how
recommendations were being followed in primary care,
60% of the patient samples had at least one total choles-
terol measurement. Older patients had also undergone
more cholesterol tests than younger patients [24]. Svilaas
found a lower barrier to administer lipid-lowering drugs
from 1995 onwards [21]. The increase in the prescribing
practices of lipid lowering drugs has been described in
several studies. Baxter describes an exponential increase
from 1994 on [25]. According to information from the
General Practice Research Database in 228 practices in
England and Wales, there was more than a 10-fold
increase in statins prescribing by GPs between 1991 and
1997 [26]. Of 114 patients with a history of coronary
heart disease and taking lipid-lowering drugs, only 44%
had a total cholesterol level below 190 mg/dl [27].
Conclusion
It is possible that in this study population it was relatively
easy for GPs to define a cardiovascular risk profile for their
patients. They had access to the cholesterol levels of more
than half of their patients over the age of 25. The risk pro-
file can be further refined by means of additional ques-
tions. GPs have dramatically changed their attitude
concerning the testing of cholesterol levels, but still fail to
achieve the targets for optimal lipid-lowering treatment in
approximately half of the treated patients. Therefore, it is
advisable for professional education to concentrate first
and foremost on the use of published guidelines among
physicians prescribing in the primary care setting.
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